

# Letters to the Editor

## Chemical Sterilization in Nursing Homes

### To the Editor:

A recurring area requiring resolution in infection control in long-term care facility (SNF) is the status of "cold sterilization." (1) Is there a place? (2) Is its value limited? (3) How effective?

You have been most gracious, informative, and have resolved a great number of problems that we, as members of infection control committees, have welcomed.

**Harry J. Silver, MD**  
Los Angeles, California

*Philip W. Smith, MD responds to Dr. Silver's questions:*

"Cold sterilization" generally refers to chemical sterilization as opposed to heat sterilization (autoclaving). Chemical sterilization is less reliable than heat sterilization, and careful attention must be paid to precleaning of the object, concentration and freshness of chemical agent, time of contact, and physical factors such as temperature. Chemical sterilization is of value particularly with equipment that cannot tolerate autoclaving without mechanical damage.

The long-term care facility will have less need for sterile equipment than the acute care hospital. Nevertheless, nursing homes still must follow established guidelines<sup>2-3</sup> for sterilizing critical medical devices (eg, lumbar puncture needles, surgical instruments) and high-level chemical disinfection of semicritical medical devices that contact mucous membrane surfaces (eg, thermometers, respiratory therapy equipment).


### REFERENCES

1. Vesley D, Green VS: Sterilization, disinfection and cleaning technique, in Bond RG, Michaelsen GS, DeRoos RL (eds): *Environmental Health and Safety in Health Care Facilities*. New York, MacMillan Publishing Company, 1973, pp 48-64.
2. Garner JS, Favero MS: Cleaning, disinfecting and sterilizing patient-care equipment. *Centers for Disease Control Guideline for Handwashing and Hospital Environmental Control*. Atlanta, 1985.
3. Rutala WA: Disinfection, sterilization and waste disposal, in Wenzel RP (ed): *Prevention and Control of Nosocomial Infections*. Baltimore, Williams and Wilkins, 1987, pp 257-282.

**Philip W. Smith, MD**  
University of Nebraska  
College of Medicine  
Omaha, Nebraska

## Protective Ribs for Male Connectors

Most of the currently used connectors for IV lines are not well protected against accidental contamination. This pertains to urinary and peritoneal catheters, as well as most other infusion or drainage systems. The male portions of the connectors are particularly vulnerable to accidental contact with the environment, eg, the fingers of caretakers or the patients themselves under the conditions of home therapy. Contamination of catheter hubs is a well-documented mechanism for catheter sepsis,<sup>1-3</sup> and is a major factor in causing the dangerous and expensive complication of central line infection.<sup>4</sup> Conceivably, the contamination of the male portion of such connectors should be prevented by protecting the connectors with overlapping ribs. Such separated ribs would have the advantage of not providing a reservoir for fluid collection and subsequent growth of micro-



Male connector protected by overlapping ribs. Threads on the underside of the rib: engage with the standard female Luer connection.

organisms. Such a proposal has been made previously,<sup>5</sup> but the proposed mechanism against accidental disconnection was too cumbersome to be put into practice. An improved solution is suggested in the figure. The male portion of the connector is protected by overlapping ribs. Threads on the underside of the ribs engage with a standard female Luer connection. The connection is rapidly and easily

secured by a clockwise turn and opened by a counterclockwise turn.

The general compatibility and safety features of this system should make it ideal for clinical use.

#### REFERENCES

1. Sitges-Serra A, Jaurrieta E, Linares J, et al: Bacteria in total parenteral nutrition catheters: Where do they come from? *Lancet* 1983; 1:531.
2. Sitges-Serra A, Linares J, Garau J: Catheter sepsis: The clue is the hub. *Surgery* 1985; 97:355-357.
3. Linares J, Sitges-Serra A, Garau J, et al: Pathogenesis of catheter sepsis: A prospective study with quantitative and semiquantitative cultures of catheter hub and segments. *J Clin Microbiol* 1985; 21:357-360.
4. Maki DG, Ringer M: Evaluation of dressing regimens for prevention of infection with peripheral intravenous catheters. *JAMA* 1987; 258:2396-2403.
5. Walterspiel JN: Protective ribs for connectors. *Infect Control* 1986; 7:564.

**Juan N. Walterspiel, MD**  
University of South Alabama  
Mobile, Alabama

## Hepatitis B and Dialysis Patients

#### To the Editor:

Should dialysis patients who are HBSAg negative receive hepatitis B vaccine prior to therapy or on initiation of therapy? Are "booster" injections indicated during the ongoing therapy if they remain negative?

**Harry J. Silver, MD**  
Los Angeles, California

*Bruce Hamory, MD, FACP responds to Dr. Silver's questions:*

Hepatitis B remains a problem for both patients and staff in dialysis units. Additional evidence from a statewide study of hepatitis B in Minnesota suggested that the presence of a dialysis unit in a hospital also carried an increased rate of hepatitis B for the entire hospital as compared with hospitals without hemodialysis units.<sup>1</sup> Patients who lack antibody to surface antigen (anti-Hb<sub>s</sub>) are susceptible to hepatitis B and should be vaccinated.

Because patients on dialysis respond less well to vaccine than do otherwise healthy persons, vaccination with twice the usual antigen dose (40 µg per injection) is strongly recommended for this group. Several studies

have examined the relative schedules of vaccination for patients on hemodialysis and have found that the length of time on dialysis did not influence the rate of seroconversion.<sup>3,4</sup> These studies suggested that patients who produced low-level antibody responses to vaccine could have their antibody levels increased by booster doses, but that patients who did not produce any antibody in response to the first three doses of vaccine failed to make antibody even following two additional doses.

Hamilton et al<sup>5</sup> have examined the relative efficiencies of plasma-derived and recombinant vaccines as well as the effect of serum creatinine upon vaccine response. Patients not yet on dialysis appeared to respond to vaccines with higher titers of antibody than did patients on dialysis. Plasma-derived vaccine provided a stronger antibody response than did recombinant vaccine in this study.

Therefore, I suggest that patients be offered vaccination with one of the available hepatitis B vaccines as soon as it can be determined that they will clearly require hemodialysis. My own preference in this situation would be to use the plasma-derived vaccine because of the larger amount of antigen contained in it. Since the duration of antibody sufficient to protect against viral hepatitis is related to the height of the initial antibody response, a recheck of the titer six weeks after vaccination, and at some interval such as yearly thereafter, should be enough to assess the timing of any booster dose needed.

#### REFERENCES

1. Osterholm MT, Garayalde SM: Clinical xiral hepatitis B among Minnesota hospital personnel. *JAMA* 1985; 254:3207-3212.
2. Centers for Disease Control: Recommendations for protection against viral hepatitis. *MMWR* 1985; 34:313-324, 329-335.
3. Carreno V, Mora I, Sanchez Sicilia L, et al: Vaccination against hepatitis B in renal dialysis units: Short or normal vaccination schedule? *Clin Nephrol* 1985; 24:215-220.
4. Kohler H, Arnold W, Renschin G, et al: Active hepatitis B vaccination of dialysis patients and medical staff. *Kidney Int* 1984; 25:124-128.
5. Seaworth B, Drucker J, Starling J, et al: Hepatitis B vaccines in patients with chronic renal failure before dialysis. *J Infect Dis* 1988; 157:332-337.

**Bruce Hamory, MD, FACP**  
Hospital Epidemiologist  
Milton S. Hershey Medical Center  
Hershey, Pennsylvania

## Universal Precautions "Clarified"?

#### To the Editor:

'The Centers for Disease Control (CDC) has recently published an update on universal precautions' with the stated purpose of "clarifying" its definition of universal precautions in health care settings. Unfortunately, however, I find several points in the update particularly disturbing and potentially counter-productive to the establishment of sound infection control practices.

1. Blood is considered the single most important source of blood-borne pathogens, and body fluids such as feces, nasal secretions, sputum, sweat, tears, urine, and vomitus are exempt from universal precautions except in the presence of "visible blood." The practicality of such a recommendation should be questioned. Blood that is visible to one person may not be visible to another, depending on how closely the body fluid is examined, the visual acuity of the observer, and available lighting. Moreover, devising a new category of "body fluids to which universal precautions do not apply" may imply that it is safe to touch such fluids unless contaminated by visible blood. Aside from downplaying the potential risk of acquiring other unsuspected nonblood-borne pathogens, (eg, Herpes simplex, *Salmonella*, hepatitis A), this recommendation also seems to ignore the possibility that, as in the case of hepatitis B,<sup>2</sup> blood may be diluted until it is no longer visible while still containing infectious particles.

2. The CDC also describes "body fluids to which universal precautions apply" regardless of the presence or absence of blood (eg, cerebral spinal fluid, synovial fluid, pleural fluid, peritoneal fluid, pericardial fluid and amniotic fluid), since the risk of transmission of HIV and hepatitis B from these fluids is unknown.

Practically speaking, how can infection control practitioners ask health care workers to remember body fluids to which universal precautions apply regardless of the presence or absence of visible blood and those to which such precautions do not apply except in the presence of visible blood, when